- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Hyperkalemia and Heart Failure Insights
A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart failure (HF), revealing important associations between baseline characteristics and hyperkalemia risk while demonstrating the drug's complex effects on potassium homeostasis.
Video content above is prompted by the following:
- What methodological considerations and unique insights emerged from the FINEARTS-HF trial's investigation of hyperkalemia risk, and how did the study design address the relationship between potassium levels and clinical outcomes?
- What baseline characteristics were associated with a higher risk of developing hyperkalemia in the FINEARTS-HF trial, and how might these findings inform the management of patients with HF?
- How did the impact of finerenone on potassium levels and hyperkalemia-related outco-mes differ from placebo, and what are the implications for its clinical use in patients with heart failure?
BMI Screening Overlooks Excess Adiposity in Children Without Obesity
September 8th 2025While body mass index (BMI) accurately identified excess adiposity in nearly all children and adolescents with obesity, it failed to detect many of those without obesity who still had excess body fat.
Read More
Economic Burden Is Greater Among Patients With Ovarian Cancer Receiving BRCA Testing
September 4th 2025Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later lines of treatment (LOT).
Read More
